,30 Although no TP53-targeted therapies are currently approved in breast cancer, emerging trials—such as the Phase II study (NCT03358017) of atorvastatin and zoledronic acid—offer potential by targeting the mevalonate pathway and mutant oncogenes. The gene discussed is TP53; the disease is breast cancer.